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Department of Medical Sciences, University of Trieste-Trieste, ItalyFor more than three decades patients diagnosed with stage III sub-classify that stage with respect to the number of the involved
colorectal cancers have undergone adjuvant chemotherapy based on
ﬂuoropyrimidines (5-FU) and more recently in combination with
oxaliplatin (Dienstmann et al., 2015). Overall that treatment has
reduced the risk of tumor recurrence and improved survival for patients
with resected colon cancer, but at present no validated biomarkers are
available to predict the beneﬁt of adjuvant chemotherapy in that
group of patients. Up to now most efforts in CRC have been made to
predict response to anti-EGFR therapy which is recommended now
only to wild type KRAS and NRAS patients, but will most likely be
followed by BRAF and PIK3CA in the near future (De Stefano and
Carlomagno, 2014). For conventional 5-FU chemotherapy no compan-
ion biomarkers are available to predict therapy response, either for
adjuvant or for curative protocols. Molecular heterogeneity of colon
cancers is themain factor affecting the differential response to adjuvant
chemotherapy. There are a lot of scientiﬁc articles reporting on biomol-
ecules which can predict the response of that therapeutic approach.
Among them MSI status (microsatellite instability) has already been
shown to inﬂuence survival and response to adjuvant infusional 5-FU
in colon cancer patients (Sargent et al., 2010) since patientswithMSI tu-
mors have better outcomes as compared with patients withmicrosatel-
lite stable (MSS) tumors. However, the improved prognosis is abrogated
in the face of adjuvant 5-FU treatment (Sargent et al., 2010). In addition,
thymidylate synthetase, EGFR polymorphisms and many others have
been shown to inﬂuence progression free survival and therefore
response to adjuvant treatment to 5-FU, but frequently with controver-
sial results. In spite of the extensive scientiﬁc production no consensus
on the use of a particular biomarker for therapy beneﬁt prediction has
been obtained. One of the reasons is that in several studies the impact
of adjuvant 5-FU chemotherapy referred to speciﬁc biomarkers was
not addressed to speciﬁc subgroups (stage II versus stage III patients).
The discrimination between stages II and III is relevant because these
two stages differ both at the clinical–biological level and at the molecu-
lar level. Moreover, prognostic markers for stage III have been reported
to have no signiﬁcance for stage II cancers (Javle, 2010).
In this issue of EBioMedicine, Kandioler et al. analyzed TP53 muta-
tions which produce a partial functionality of the protein (decreasing
its transcriptional activity to less than 75%) in stage III colon cancer
patients (Kandioler et al., in press). Relevant of this study is that the
authors conﬁned their analyses only to stage III patient and that theyDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.06.003.
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chemotherapy only in N1 wild type patients in comparison to TP53
mutated ones. That beneﬁt was lost when considering N2 patients
highlighting that subgrouping is also relevant for N classes. There is
the possibility as in breast cancers that N1 tumors behave as N0 ones.
With respect to TP53 it plays at least 2 separate roles in the responses
to therapeutic agents: it is an important component of cellular check-
points, and it can mediate apoptosis. The response to individual drugs
is determined by which of these 2 functions is paramount and for 5-
FU the apoptotic effect is predominant (Bunz et al., 1999). The effect
of mutation reducing TP53 activity seems to cause resistance to the ap-
optotic effects of FU, hence a diminished therapy beneﬁt (Bunz et al.,
1999). Nonetheless, the mutational status at TP53 could predict the
beneﬁt to adjuvant chemotherapy only in stage III patients with less
than 3 positive lymph nodes and not in patients with more than 3
lymph nodes involved, for whom the authors did not expect any beneﬁt
from adjuvant chemotherapy. Surely, the response to all drugs, includ-
ing 5-FU, is complex and unlikely to be completely explained by any
single genetic alteration. Sub-classiﬁcation in lymph node classes has
proved to be a meaningful variable to understand response to 5-FU
adjuvant chemotherapy. Possibly, tumors' heterogeneity with further
additional “spatial” alterations in different metastatic sites could
account for this result. The present study (Kandioler et al., in press)
highlights that “early” advanced stage III tumors are different from N2
tumors and that N1 patients with TP53 mutations are less likely to
respond to 5-FU adjuvant therapy in comparison to wild type. If
conﬁrmed it could have a considerable impact on clinical practice.
Although those results are relevant additional studies are needed to
sub-classify stage III colon cancer patients and deﬁne the group of
patients who will beneﬁt from adjuvant treatment in routine clinical
practice.
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